The Chemours Company (NYSE:CC) Shares Purchased by Twelve Points Wealth Management LLC

Twelve Points Wealth Management LLC boosted its stake in shares of The Chemours Company (NYSE:CC) by 42.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,325 shares of the specialty chemicals company’s stock after buying an additional 23,490 shares during the period. Twelve Points Wealth Management LLC’s holdings in Chemours were worth $1,324,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. FMR LLC raised its position in shares of Chemours by 3.5% during the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock valued at $368,650,000 after buying an additional 618,361 shares during the period. Geode Capital Management LLC increased its stake in Chemours by 1.2% during the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock worth $50,646,000 after acquiring an additional 28,803 shares during the last quarter. Appian Way Asset Management LP purchased a new stake in Chemours in the third quarter valued at $34,151,000. Vision One Management Partners LP acquired a new position in shares of Chemours in the 3rd quarter valued at $28,252,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Chemours by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company’s stock worth $24,974,000 after purchasing an additional 32,590 shares during the period. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Morgan Stanley reduced their price objective on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Truist Financial began coverage on shares of Chemours in a research note on Tuesday. They issued a “buy” rating and a $27.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Chemours in a research report on Thursday, December 12th. Mizuho cut their target price on Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Chemours presently has a consensus rating of “Hold” and an average target price of $24.11.

Insider Activity

In related news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.47% of the company’s stock.

Chemours Stock Down 1.8 %

Shares of Chemours stock opened at $18.76 on Wednesday. The Chemours Company has a 52-week low of $15.10 and a 52-week high of $31.76. The company has a 50 day moving average of $19.18 and a 200 day moving average of $19.55. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The company has a market capitalization of $2.80 billion, a P/E ratio of 37.51 and a beta of 1.83.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the prior year, the company posted $0.64 earnings per share. Chemours’s revenue for the quarter was up .9% compared to the same quarter last year. As a group, research analysts forecast that The Chemours Company will post 1.19 EPS for the current fiscal year.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.